CD200R1 and Stroke: Future studies measuring soluble CD200 levels in the plasma of stroke patients could determine whether this molecule serves as a potential biomarker of neuronal injury or, perhaps, could be used to identify patients at risk for systemic immune suppression and subsequent infections, opening new doors to CD200R1 therapies.